Exkivity, an anticancer drug targeting EGFR exon 20 insertion mutations, can be prescribed at general hospitals. According to related industries, Exkivity, a treatment for non-small cell lung cancer with an EGFR exon 20 insertion mutation of Takeda Pharmaceutical Korea, passed the Drug Committees of the National Cancer Center, Seoul National University Hospital, and Samsung Seoul Hospital. As the insurance benefit registration process is currently in progress, it seems to focus on creating a prescription environment. Exkivity targets the same biomarker as Janssen Korea's Rybrevant, but with the difference that it is an oral drug.

EGFR Exon 20 insertion mutation is a new biomarker that has recently attra